Payment overview · 2025
General Payments
$1,216.20
61 reported records · 20 companies
Healthcare provider profile · identity verified
Jennifer Crosby
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FLINT, MI · NPI 1154778835
Verified facts
What the public records show
CMS Open Payments records show Jennifer Crosby received $1,216.20 in general payments during 2025 across 61 reported records.
Vanda Pharmaceuticals Inc. accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $221.55 | 18.2% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $146.34 | 12.0% | 11 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.21 | 10.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $101.00 | 8.3% | 6 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $72.19 | 5.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.29 | 5.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $57.98 | 4.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.03 | 4.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.11 | 4.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.47 | 4.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.25 | 4.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.55 | 3.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $37.28 | 3.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.00 | 3.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.74 | 2.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.51 | 1.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.74 | 1.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.50 | 1.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.60 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.86 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,216.20 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $221.55 | 11 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $146.34 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $85.53 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $81.58 | 5 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $72.19 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.29 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.29 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $57.98 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.47 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.68 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 297 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 66 |
| Lisinopril | Lisinopril | 220 | 66 |
| Omeprazole | Omeprazole | 215 | 59 |
| Gabapentin | Gabapentin | 196 | 44 |
| Montelukast Sodium | Montelukast Sodium | 170 | 41 |
| Simvastatin | Simvastatin | 161 | 47 |
| Metformin Hcl | Metformin Hcl | 160 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 46 |
| Losartan Potassium | Losartan Potassium | 155 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 30 |
| Furosemide | Furosemide | 138 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 136 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 31 |
| Trazodone Hcl | Trazodone Hcl | 117 | 27 |
| Ibuprofen | Ibuprofen | 107 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 102 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 33 |
| Meloxicam | Meloxicam | 81 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 30 |
| Potassium Chloride | Potassium Chloride | 75 | 21 |
| Eliquis | Apixaban | 74 | 18 |
| Carvedilol | Carvedilol | 70 | 19 |
| Alprazolam | Alprazolam | 68 | 19 |
| Sertraline Hcl | Sertraline Hcl | 68 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 15 |
| Baclofen | Baclofen | 65 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 24 |
| Famotidine | Famotidine | 61 | 19 |
| Atenolol | Atenolol | 57 | 13 |
| Tramadol Hcl | Tramadol Hcl | 57 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Trulicity | Dulaglutide | 56 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 14 |
| Allopurinol | Allopurinol | 51 | 15 |
| Buspirone Hcl | Buspirone Hcl | 51 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 16 |
| Methylprednisolone | Methylprednisolone | 48 | 39 |
| Prednisone | Prednisone | 47 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 11 |
| Donepezil Hcl | Donepezil Hcl | 41 | 14 |
| Nitroglycerin | Nitroglycerin | 41 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 13 |
| Fluconazole | Fluconazole | 38 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 15 |
| Bupropion Xl | Bupropion Hcl | 35 | 11 |
| Ezetimibe | Ezetimibe | 34 | 12 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 15 |
| Alendronate Sodium | Alendronate Sodium | 33 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 23 |
| Ozempic | Semaglutide | 30 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 26 |
| Glipizide | Glipizide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Primidone | Primidone | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,216.20 · 61 records | Vanda Pharmaceuticals Inc. | AIRSUPRA, BREZTRI, CAPLYTA, DAYBUE, FANAPT, INSPIRE, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Veozah, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error